Establishing safety and efficacy of an improved Asparaginase in dog models: final preparation for Phase I clinical trial

Doctoral project Jolien Vanhooren

Long non-coding RNAs as therapeutic targets in the treatment of childhood leukemia

Clinical implementation of drug response profiling to improve survival rates in relapsed or refractory acute leukemia in children and adolescents

Diagnosing HEreditary predisposition syndromes for Childhood cancer: Implementation in clinical PRactice (DHECIPR)

Doctoral project Hetty Helsmoortel

Doctoral project Laurens Van Camp

Integration of genome, epigenome, and transcriptome in juvenile myelomonocytic leukemia (JMML) and functional analysis of circular RNAs as novel biomarkers and/or therapeutic targets.

Optimization of asparaginase therapy in childhood acute lymphoblastic leukemia

Targeting the micro-environment in acute lymphoblastic leukemia

The role of GATA3 in acute lymphoblastic leukemia.

A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis

Cofunding Core Facility - Patient-derived xenograft models

Evaluating the predictive power of a set of adrenergic and mesenchymal coding - and - noncoding RNAs in neuroblastoma.

Multi-Omics Profiling in Juvenile Myelomonocytic Leukemia: Unveiling Pathobiology for Refined Patient Management.

NOTCH1 FUSIONS IN PEDIATRIC T-CELL LYMPHOBLASTIC LYMPHOMA: IMPACT ON BIOLOGY AND TREATMENT.

Preclinical evaluation of newly identified therapeutic targets in pediatric acute myeloid leukemia

Preclinical study of TARP-directed cellular and nanobody therapy in pediatric AML: improving survival and quality-of-life

Research assignment of Prof. dr. Tim Lammens, framing the ongoing clinical-translational research at the Department of Pediatric Hematology-Oncology and Stem Cell Transplantation

Stichting Me To You : Research Grants Jolien Vanhooren: "Deciphering the role of Nidogen-1 in pediatric acute myeloid leukemia"

The impact of magnetic particulate matter (mPM) pollution as a contributing factor for development of childhood cancer: an in vitro and in vivo molecular and cellular analysis.

Translational research in pediatric hematology-oncology: towards improved survival and less toxicity.

A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapies

Minimal residual disease targeting in T-cell acute lymphoblastic leukemia

Preclinical validation of a less toxic variant for paediatric leukemia

Predisposition in a family with two pediatric patients with Hodgkin lymphoma Non-Burkett

The role of non-coding RNA in juvenile myelomonocytic leukemia

The role of non-coding RNA in juvenile myelomonocytic leukemia

Towards clinical testing of novel stabilized less toxic asparaginases for the treatment of acute lymphoblastic leukemia

Evaluation of the prognostic value of the leukemic stem cell (LSC) and pre-leukemic hematopoietic stem cell (pre-L HSC) for minimal residual disease monitoring and clinical management of pediatric acute myeloid leukemia patients

Research Assignment dr. Tim Lammens ihkv the ongoing clinical-translational research at the department of Pediatric Hematology-Oncology and Stem Cell Transplantation

The use of a less toxic alternative asparaginase variant to treat metastatic breast cancer